HUMAN NORMAL IMMUNOGLOBULIN (IVIG)
Secondary Immunodeficiency
Takedaother_biologicalPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Secondary Immunodeficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ZINC SULFATE Fakultas Kedokteran Universitas Indonesia | Phase 4 | BB |
CYCLOSPORIN A West China Hospital | Phase 4 | B |
Igpro20 CSL Behring | Phase 3 | B |
Histamine Sahlgrenska University Hospital | Phase 2 | CCC |
BLOOD PLASMA Assistance Publique - Hôpitaux de Paris | D | |
Hizentra Rochester General Hospital | Phase 2/3 | NR |
Same molecule, other indications
HUMAN NORMAL IMMUNOGLOBULIN (IVIG) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →